Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Pfizer (PFE - Analyst Report) is scheduled to report its fourth quarter 2012 results on Jan 29, 2013 before the opening bell.
Last quarter, the company posted a 1.92% positive surprise. Let’s see how things are shaping up prior to the announcement.
Growth Factors this Past Quarter
Last quarter, Pfizer posted earnings, of 53 cents per share, a penny above the Zacks Consensus Estimate. However, earnings fell 12% year over year. Results were hit by the loss of exclusivity of certain products and the unfavorable impact of currency fluctuation. We believe that the near-term earnings will be driven by cost cutting efforts and share repurchases. However, longer-term growth will depend on the success of drug development. The company’s pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.
Earnings Whispers?
Our proven model does not conclusively show that Pfizer is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method)and a Zacks Rank #1 (Strong Buy) or at least Zacks Rank #2 (Buy) or Zacks Rank #3 (Hold) for this to happen.This is not the case here as you will see below.
Zacks ESP: This is because the Most Accurate estimate stands at 44 cents, which is in line with the Zacks Consensus Estimate. This implies an earnings ESP of 0.00%.
Zacks Rank #3 (Hold): Pfizer carries a Zacks Rank of 3. The combination of Pfizer’s Zacks Rank # 3 and 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Sanofi (SNY - Analyst Report), Earnings ESP of +9.21% and Zacks Rank #2 (Buy)
Onyx Pharma Inc. (ONXX - Analyst Report), Earnings ESP of +21.43% and Zacks Rank #3 (Hold)
Astrazeneca (AZN - Analyst Report), Earnings ESP of +0.73% and Zacks Rank #3 (Hold)
Get the full Analyst Report on SNY - FREE
Get the full Analyst Report on AZN - FREE
Get the full Analyst Report on PFE - FREE
Get the full Analyst Report on ONXX - FREE